REGENXBIO Inc.

RGNXReported to SECin USCIK 0001590877Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 18. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 18
Form 4 lines at REGENXBIO Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Malzahn CraigChief Technology OfficerAdministrative$2,181234 sharesSep 3, 2026Malzahn CraigChief Technology Officer$2,181Admin · Sep 3Administrative234Sep 3, 2026
Chan MitchellChief Financial OfficerAdministrative$45,6874,902 sharesSep 3, 2026Chan MitchellChief Financial Officer$45,687Admin · Sep 3Administrative4,902Sep 3, 2026
Ciongoli Gregory Austin—Awardnothing paid69,609 sharesAug 27, 2026Ciongoli Gregory Austinnothing paidAward · Aug 27Award69,609Aug 27, 2026
Ciongoli Gregory Austin—Open-market buy$499,67653,407 sharesAug 27, 2026Ciongoli Gregory Austin$499,676Buy · Aug 27Open-market buy53,407Aug 27, 2026
Ciongoli Gregory Austin—Open-market buy$449,70649,196 sharesAug 27, 2026Ciongoli Gregory Austin$449,706Buy · Aug 27Open-market buy49,196Aug 27, 2026